Cancer Drug Patent Obvious From Earlier Study, EPO Rules
A pharmaceutical company has lost its cancer drug patent after the European Patent Office ruled that it was not inventive due to a previous study of the same treatment....To view the full article, register now.
Already a subscriber? Click here to view full article